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Purpose: To estimate the effects of heterogeneity on tumour cell sensitivity to
radiotherapy combined with radiosensitizing agents attributable to differences in
expression levels of Epidermal Growth Factor Receptor (EGFr).
Materials and methods: Differences in radiosensitivity are not limited to cells of
different cancer histotypes but also occur within the same cancer, or appear during
radiotherapy if radiosensitizing drugs are combined with ionizing radiation. A
modified biologically effective dose (MBED), has been introduced to account for
changes in radiosensitivity parameters (α and α/β) rather than changes in dose/
fraction or total dose as normally done with standard biologically effective dose
(BED). The MBED approach was applied to cases of EGFr over-expression and cases
where EGFr inhibitors were combined with radiation. Representative examples in
clinical practice were considered.
Results: Assuming membrane EGFr over-expression corresponds to reduced
radiosensitivity (αH = 0.15 Gy-1 and αH/βH = 7.5 Gy) relative to normal radiosensitivity
(α= 0.2 Gy-1 and α/β= 10 Gy), an increased dose per fraction of 2.42 Gy was obtained
through the application of MBED, which is equivalent to the effect of a reference
schedule with 30 fractions of 2 Gy. An equivalent hypo-fractionated regime with a
dose per fraction of 2.80 Gy is obtained if 25 fractions are set. Dose fractionations
modulated according to drug pharmacokinetics are estimated for combined
treatments with biological drugs. Soft and strong modulated equivalent
hypo-fractionations result from subtraction of 5 or 10 fractions, respectively.
Conclusions: During this computational study, a new radiobiological tool has been
introduced. The MBED allows the required dose per fraction to be estimated when
tumour radiosensitivity is reduced because EGFr is over-expressed. If radiotherapy
treatment is combined with EGFr inhibitors, MBED suggests new treatment strategies,
with schedules modulated according to drug pharmacokinetics.© 2012 Pedicini et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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Recently, radiobiology has been transformed thanks to new knowledge concerning cel-
lular activation processes in response to an external stimulus. This knowledge has led
to the identification of promising new drug therapies called "targeted therapy” [1].
Epidermal growth factor receptor (EGFr) has emerged as a central molecular target
for modulation during cancer therapy. The correlation between over-expression of
EGFr and clinically aggressive malignant disease suggested that EGFr was a promising
target for several epithelial tumours, which represent approximately two thirds of all
human cancers. Furthermore, the favourable interaction profile for EGFr blocking
agents combined with radiation has stimulated clinical trials in diverse anatomical sites
including head and neck, colorectal region, pancreas and lung [2], where molecular in-
hibition of EGFr signalling in combination with radiation represents a highly promising
area [3,4].
Therefore, new radiobiology studies have focussed on identifying correlations be-
tween radiosensitization and biological agents. However, these effects have not been
fully integrated into current radiobiological models [5-8]. One such model commonly
used in clinical practice, is the BED obtained from the LQ model [9], given by the fol-
lowing equation (proliferation ignored):
BED ¼ D⋅ 1þ d
α=β
 
; ð1Þ
where α and β represent intrinsic and repair cell radiosensitivity, respectively, d repre-
sents the dose per fraction and D is the total dose delivered during the radiation treat-
ment. The BED is considered a “biological dose” delivered by a particular combination
of dose per fraction and total dose to a given tissue, characterized by a given α/β ratio,
and is commonly used to equate or compare various fractionation schedules [10].
However, eq. (1) demonstrates that the same number of cells killed – the equivalent
effect – could be obtained equating the BED not only for schedules with different num-
bers of fractions and various doses per fraction, but also for schedules where the dose
per fraction is increased if a reduction in radiosensitivity results (i.e. α or β is reduced).
This could be applicable for subsets of cells that over-express EGFr, representing a
source of heterogeneity closely connected with the repopulation rate and intrinsic
radiosensitivity. However, the heterogeneous population of EGFr expression cannot be
represented by a single equation of tumour control probability (TCP), as it is intrinsic-
ally linked to a group of tumours with identical characteristics [11].
Furthermore, equations considering the radiation response that take into account dif-
ferent compartments of sensitivity within tumours [12] or a Gaussian distribution of in-
dividual radio sensitivities [13,14] cannot be used because various levels of
radiosensitivity coexist in the tumors or in the statistical sample.
Therefore, during this computational study, a new mathematical interpretation of
radiosensitivity parameters that are normally used in standard radiobiological models
(i.e. as functions of EGFr expression) is proposed using simple examples.
The final aim of the current study is to provide an additional mathematical tool that
can be used to carry out radiobiological analysis, taking into account the radioresis-
tance effects due to EGFr over-expression and/or radiosensitization effects due to EGFr
inhibitors when they are combined with radiation.
Pedicini et al. Theoretical Biology and Medical Modelling 2012, 9:23 Page 3 of 12
http://www.tbiomed.com/content/9/1/23These examples are not intended to simulate a particular type of radiotherapy treat-
ment, but are designed to demonstrate a general effect.
Materials and methods
During the current analysis two separate groups of patients with various levels of EGFr
expression were considered. For each of the EGFr groups, various values for the para-
meters α, β, were considered. This approach allowed radiobiological analysis to be con-
ducted in cases where differences in radiosensitivity occurred within the same tumour
after combined treatments comprising radiation and radiosensitizing EGFr inhibitors
[4,15,16]. In the latter case, various levels of radiosensitivity did not coexist, but they
followed one another according to the concentration of radiosensitizing drug present
during the radiotherapy session (Figure 1).
Modified BED: Effects due to a change in EGFr expression levels EGFr expression has
been assessed through intensity of staining (i.e., absent, minimal, moderate, or intense
staining) in clinical practice [17]. During the present analysis, normal and high expres-
sion levels of EGFr (i.e. below and above 50% staining) were distinguished. The sub-
script H was added to indicate high EGFr expression.
The BED for the EGFr group with high expression may be indicated as:
BEDH ¼ n⋅d⋅ 1þ d
αH=βH
 
Here, because αH and βH are lower than α and β (reduced radiosensitivity), the num-
ber of cells killed with the same dose per fraction (d) and the number of fractions (n)
were reduced with respect to standard radiosensitivity conditions. Therefore, the fol-
lowing inequality arose:
α⋅BED > αH ⋅BEDH
To obtain the same effect with an equal number of fractions, a change of dose/frac-tion is necessary. We introduce the MBED:
MBED ¼ n⋅δ⋅ 1þ δ
αH=βH
 
ð2Þ
where the dose δ, which refers to αH and βH, has the effect equivalent to d, which refers
to α and β, so that:
α⋅BED ¼ αH ⋅MBED ð3Þ
In eq. (3) the LHS provides a measure of treatment effect under standard conditionsof radiosensitivity, while the RHS represents the same effect achieved under non stand-
ard conditions of radiosensitivity.Figure 1 Schematic representation of radiosensitivity variability within a single tumour due to the
presence of varying concentrations of radiosensitizer drugs (Light gray= high radiosensitivity, dark
gray= low radiosensitivity).
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α⋅d⋅ 1þ d
α=β
 
¼ αH ⋅δ⋅ 1þ δ
αH=βH
 
;
and solving for δ
δ ¼  αH
2βH
þ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
αH
2βH
 2
þ d⋅ α
βH
þ β
βH
d
 s
ð4Þ
Therefore, the MBED distinguishes between changes in biological effect due to irrep-arable and/or reparable damage variations, rather than changes due to dose/fraction or
total dose variations. A reduction in radiosensitivity due to increased membrane EGFr
expression [11,18] implies equivalence between treatments by increasing the dose per
fraction with an equal number of fractions.
Furthermore, to obtain isoeffective treatments with a different number of fractions m
(m < n hypo-fractionation, m > n hyper-fractionation) from eq. (3), the following results:
δ ¼  αH
2βH
þ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
αH
2βH
 2
þ n⋅d
m
⋅
α
βH
þ β
βH
d
 s
ð5Þ
Modified BED: Effects due to biological drugs
Combined treatment comprising radiation and radiosensitizing EGFr inhibitor drugs
requires the daily dose that achieves the same effect without drugs to be calculated.
This will result in a calculation of the daily radiosensitivity conditions induced by the
drug compared with standard radiosensitivity.
On the basis of a preclinical assessment, we propose a method to estimate the daily
radiosensitivity when radiotherapy treatment is combined with biological drugs. Subse-
quently, the MBED method is applied to assess the changes required in terms of dose
fractionation when such daily radiosensitivity is considered.
During the first phase, survival curves obtained with various concentrations of a
monoclonal antibody (mAb) EGFr inhibitor were selected from the literature [16,18].
From these curves, using a polynomial regression, the corresponding values of α and β
were calculated (Figure 2(a)). However, the drug concentrations reported in theseFigure 2 First phase to investigate the effects EGFr over-expression on radiosensitivity of Head and
Neck cell lines. Data from literature [16,18,19] demonstrate the correlation between EGFr over-expression
and reduced cellular radiosensitivity. This situation is indicated by an upward shift of the cell survival curve
in the line over-expressing EGFr compared with normal EGFr expression. A polynomial regression allows
radiosensitivity parameters corresponding to various surviving curves to be calculated.
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bined treatment with radiation every day of treatment (Figure 2(b)).
Therefore, during the second phase, the daily in vivo concentration of EGFr inhibitor
drug was calculated from its pharmacokinetic curve and drug dosage [20]. Referring to
these daily concentrations, it is possible to interpolate plausible corresponding curves
of survival fractions, obtaining the researched values of α and β using a new polynomial
regression (Figure 3).
Subsequently, assuming a daily in vivo radiosensitivity, eq. (3) with a variable con-
centration of a radiosensitizing drug according to the weekly dosage can be written
as follows:
n⋅d⋅ αþ β⋅dð Þ ¼ nw⋅ δ1⋅ α1 þ β1⋅δ1ð Þ þ :::::þ δ5⋅ α5 þ β5⋅δ5
  
where nw (nw=m/5) represents the number of weeks of overall treatment and the
numbers 1,2,. . .,5 indicate the day of the week. In compact form, we can write:
n⋅d⋅ αþ β⋅dð Þ ¼ nw⋅
X5
i¼1
δi⋅ αi þ βi⋅δi
 
;
Therefore, an equivalent fractionation with the same number of fractions is obtainedusing the following:
d⋅ αþ β⋅dð Þ ¼ 1
5
X5
i¼1
δi⋅ αi þ βi⋅δi
 
; ð6Þ
From eq. (6), a solution with equal dose for each day is:
δ ¼ 
P
i
αi
2
P
i
βi
þ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃP
i
αi
2
P
i
βi
0
@
1
A
2
þ 5⋅d⋅ αþ β⋅dð ÞP
i
βi
vuuut ð7Þ
In addition, eq. (6) highlights the possibility of solutions with a dose adapted to thedaily radiosensitivity. By equating the effect day to day during the week, for the ith day
we obtain:
d⋅ αþ β⋅dð Þ ¼ δi⋅ αi þ βi⋅δi
 
;Figure 3 Second phase to estimate the effects on radiosensitivity of variable concentrations of
mAb EGFr inhibitor in Head and Neck cell lines. Surviving fraction curves corresponding to the daily
concentrations of mAb from pharmacokinetics curves [20] are obtained by interpolation. The following
concentrations of EGFr mAb inhibitor are obtained: 100, 61, 37, 22 and 13 nM. The corresponding
polynomial regression curves provide α/β= 5, 9, 12, 14 and 15 Gy (with α= 0.2 Gy-1), with respect to
untreated cells with α/β= 16 Gy (α= 0.2 Gy-1).
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δi ¼  αi2βi
þ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
αi
2βi
 2
þ d⋅ α
βi
þ β
βi
d
 s
ð8Þ
Eq. (8) leads toamodified fractionationmodulatedaccordingtothepharmacokineticsof the
drugcombinedwithradiation.Foraschedulewithdifferentnumbersoffractions:
δi ¼  αi2βi
þ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
αi
2βi
 2
þ n⋅d
m
⋅
α
βi
þ β
βi
d
 s
ð9Þ
This solution leads to a modulated hypo-fractionation if the number of weeks is lessthan the standard fractionation (vice versa for the hyper-fractionation).
Eq. (7) and eq. (9) represent dose values that have the same effect. However, as
in the drug is also absorbed by normal tissue cells, these cells will show increased
radiosensitivity. Therefore, modulated dose fractionation with a reduced dose of ra-
diation corresponding to higher radiosensitivity could lead to a reduction in harm-
ful effects.
This proposal could be verified through clinical trials.
Results
This section discusses results from representative examples occurring in clinical prac-
tice. Schedules with the equivalent effect of 30 fractions of 2 Gy/fraction (assumed as a
reference standard regime) were calculated. To analyze an increase in radiosensitivity, a
change in α or β, and consequently a change in α/β, has been assumed to simplify the
calculations without losing generality.
For examples 3, 4 and 5, substantial changes in β alone has been adopted, assuming
that data were obtained from the polynomial regressions of curves depicted in Figure 3.
Of note, the unchanged α, β (without polynomial regression) and the fractionation
schemes assumed in these examples are plausible but should not be considered as
recommendations for real clinical situations.Figure 4 Weekly dose/fraction as a function of radiosensitivity for modified fractionations with (a)
same number of fractions as the reference fractionation (Example 1) and (b) hypo-fractionation with
one week less than reference fractionation (Example 2).
Figure 5 Dose/fraction as a function of daily radiosensitivity for modulated fractionations with (a)
same number of fractions as the reference schedule (Example 3: 6 weeks), (b) hypo-fractionation
with one week less than the reference schedule (Example 4: 5 weeks) and hypo-fractionation with
two weeks less than the reference schedule (Example 5: 4 weeks). The grey lines represent
radiosensitivity corresponding to the pharmacokinetics curves of absorption for the EGFr mAb inhibitor.
Abbreviations: (1) α/β= 5 Gy; (2) α/β= 9 Gy; (3) α/β= 12 Gy; (4) α/β= 14 Gy; (5) α/β= 15 Gy.
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These figures present the extent of dose for fraction as a function of weekly or daily
radiosensitivity; tables 1 and 2 present numerical results.
Example 1
In this example a selection of patients that should be treated with the reference sched-
ule (consisting of 30 fractions of 2 Gy/fraction on PTV) was assumed. Patients in the
first subset (G1) were considered to have normal EGFr expression on clonogenic
tumour cells, with radiosensitivity corresponding to α= 0.2 Gy-1, β= 0.02 Gy-2 (α/β= 10
Gy). In addition, we considered a second subset of patients (G2) as presenting with
EGFr cell membrane over-expression, resulting in a reduction of radiosensitivity with
αH= 0.15 Gy
-1, βH= 0.02 Gy
-2 (α/βH= 7.5 Gy).
Therefore, with respect to the reference schedule, the effect for the subset G1 would be:
α⋅BED ¼ 0:2⋅30⋅2⋅ 1þ 2
10
 
¼ 14:4
Owing to the reduction of the α component of irreparable damage, the same scheduleused for group G2 will produce the following effect:
αH ⋅BEDH ¼ 0:15⋅30⋅2⋅ 1þ 27:5
 
¼ 11:4
with a noticeable reduction in the effect of overall treatment.Table 1 Numerical results for Examples 1 and 2
EGFr expression α(Gy-1) β(Gy-2) α/β(Gy) dex1(Gy) dex2(Gy)
Normal 0.2 0.02 10 2.00 2.33
Over-expressed 0.15 0.02 7.5 2.42 2.80
Abbreviation: dex1 and dex2=doses from MBED for Example 1 and 2, respectively.
Table 2 Numerical results for Examples 3, 4 and 5
Day α(Gy-1) β(Gy-2) α/β(Gy) dex3(Gy) dex4(Gy) dex5(Gy)
Monday 0.2 0.040 5 1.68 1.94 2.31
Tuesday 0.2 0.022 9 1.86 2.18 2.62
Wednesday 0.2 0.017 12 1.93 2.27 2.74
Thursday 0.2 0.014 14 1.98 2.32 2.81
Friday 0.2 0.013 15 1.99 2.34 2.84
Abbreviation: dex3, dex4 and dex5=doses from MBED for Example 3, 4 and 5, respectively.
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group G1 (with the same number of fractions taken in the reference treatment), the dose
per fraction should be increased by imposing condition (3). Then, from eq. (4), we obtain:
δ ¼ 2:42Gy
To achieve the same effect on the PTV, 30 fractions of 2.42 Gy/fraction should begiven to compensate for reduced radiosensitivity due to over-expression of membrane
EGFr (Table 1 and Figure 4).
The new schedule will be not equivalent in terms of toxicity to organs at risk (OAR).
Therefore, the plan will require re evaluation of the harmful effects for OARs. In the
opposing situation, that is for an increase of radiosensitivity in the clonogens of G2
compared with G1 (owing to a radiosensitizing drug), one can adopt the same proced-
ure. In such cases, the equivalent effect on the PTV, with the same number of fractions,
will be reached by reducing the fraction dose.
Example 2
For the same subsets of patients used in Example 1, we analyzed a hypo-fractionated
schedule that lasted for one week less for patients in G2, with the same effect as the
standard schedule for patients in G1. In the hypo-fractionation schedule, the number
of fractions was m=5(nw-1) = 55 = 25 fractions.
Applying eq. (5) we obtain:
δ ¼ 2:80Gy
therefore, the hypo-fractionated schedule for patients in G2 will be equivalent to the
standard schedule for patients in G1 if 25 fractions of 2.80 Gy/fraction are given. If
α/β= 10 Gy and a normal radiosensitivity is assumed, we would obtain:
0:2⋅30⋅2⋅ 1þ 2
10
 
¼ 0:2⋅25⋅d⋅ 1þ d
10
 
;
from which:
d ¼ 2:33Gy
which would underestimate the dose required to achieve the same effect on the
PTV (Table 1 and Figure 4).
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In this example we refer to group G2 having substantial membrane EGFr over-expres-
sion, with αH= 0.2 Gy
-1 and αH/βH= 16 Gy (similar estimated α/β values are reported in
the literature [21]). We compare the reference treatment with a combined treatment
comprising radiation and biological drugs that produce an increase in radiosensitivity.
In addition, we assume a weekly drug dosage with a pharmacokinetics curve showing
maximum absorption during the first day of treatment [20]. The weekly radiosensitivity
is assumed to be that described by the set of values reported in Table 2.
The equivalent treatment with the same number of fractions is obtained using eq. (7).
In this case, a constant dose for each day is obtained, equaling the global effect.
δ ¼ 1:88Gy
Subsequently, using eq. (8), a dose modulated according to the drug pharmacokinet-
ics is obtained, equaling the effect for each day of treatment. Results are presented in
Table 2 and Figure 5.
Examples 4 and 5
The equivalent global effect of the reference schedules could be obtained by subtracting
one or two weeks of treatment from eq. (9), with a modulated soft hypo-fractionation
(5 weeks) and with a modulated strong hypo-fractionation (4 weeks), respectively. The
results are presented in Table 2 and Figure 5.
Discussion
During practical applications of radiobiological models, the main difficulty is to decide
which parameter values should be included in individual calculations. It is important to
clarify that population based estimates of the α/β value represent averages, and that
values are likely to vary between and within tumour types. It is clear that the assump-
tion of a single value for α or α/β is a simplification and this could have a considerable
impact on the predictive use of BED when deciding on dose fractionation [22].
However, recent knowledge concerning molecular mechanisms allows new develop-
ments to be explored and provides important information relating to the intrinsic
radiosensitivity and fractionation sensitivity. Cell studies in vitro demonstrate that dif-
ferences in radiosensitivity occur among cell lines derived from different types of
tumours or from the same type of tumour, and during irradiation when combined
treatments using radiation and radiosensitizing drugs are utilised [16,23-25].
These considerations may lead the way for new studies concerning evaluation of α
and β, in which cellular radiosensitivity is modified using known concentrations of
radiosensitizing drugs, as described in Figure 4 and Figure 5.
Therefore, the historical inability to distinguish among effects resulting in differences
in radiosensitivity could be overcome through new knowledge concerning heterogen-
eity [26,27]. These effects are well known from preclinical studies, and could be used to
reduce uncertainties and investigated through clinical trials [28]. The ideal situation
could be to use assay methods to allocate patients to various treatment schedules on
the basis of individual measurements of tumour cell radiosensitivity (for example, due
to varied expression of EGFr) or absorption of drugs. This approach is expected to be
applied in the foreseeable future.
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named MBED, was introduced during this computational study to take account of in-
trinsic differences in radiosensitivity.
The requirement to introduce MBED arises because radiosensitivity is usually consid-
ered to be fixed for a cell type and constant during any radiation treatment. For this
reason, α and β are considered fixed values with considerable uncertainty. Therefore, in
the standard use of the BED, the hypothesis that one fractionation is equivalent to an-
other underlies the assumption that the values of α and β are the same: to have the
same effect – resulting in the same number of cells being killed – changing the dose
per fraction, one must alter the number of fractions.
Herein, it is argued that for various values of radiosensitivity, the same number of
cells can be killed with the same number of fractions by varying the dose per fraction.
This requires identification of prognostic parameters such as the over-expression of
EGFr, which allows the radiosensitivity of the individual patient to be classified and the
most appropriate radiation dose fractionation to be identified.
The results of this study demonstrate that for a subset of patients presenting with
EGFr cell membrane over-expression, resulting in reduced radiosensitivity with respect
to a subset of patients with normal EGFr expression of clonogenic tumour cells, the
dose per fraction should be increased to produce the same therapeutic effect with the
same number of fractions taken in the reference treatment.
When radiation is combined with a biological drug that produces an increase in radio-
sensitivity, depending on the drug dosage, the equivalent treatment with the same num-
ber of fractions is obtained by a dose of radiation modulated according to drug
pharmacokinetics.
The dose needs to be increased if the number of fractions is reduced.
In the examples reported herein, the absorption of EGFr inhibitors was considered for
cancer cells alone. In general, cells of normal tissues also absorb the drug. In particular,
EGFr is over-expressed in skin cells. Therefore, the effect of increased radiosensitivity
will affect these cells, and modulated fractionations with a lower dose of radiation corre-
sponding to higher radiosensitivity could lead to a reduction of harmful effects.
With MBED, this study was not intended to implement a finely tuned model based
on accurate data obtained from preclinical analysis. The aim was to demonstrate the
potential of the model and its malleability in terms of including further information
that selective preclinical studies may provide [19].
In addition, previous analyses have depended on the validity of the LQ model, which
has limitations. In particular, the LQ model used during this study does not include the
time factor. In the generalized LQ model [5,10] the temporal factor is affected by differ-
ences in EGFr expression due to its influence on potential doubling time, TD [29-32].
This temporal factor can be particularly important when the MBED model is used to
compare treatment schedules that differ in terms of overall treatment times, tumour
control or acute effects (where time dependent repopulation may be important). The
difference of doubling time between the High EGFr group and the Low EGFr group
identified during the current study will be investigated further in new studies. This dif-
ference in terms of TD can be transformed into an equivalent dose that would be
required to offset the modified proliferation occurring in one day. The value of this
equivalent dose can be taken into account during the previous analysis.
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sideration of the relevant physical dose variations, the possible range of biological para-
meters and pertinent clinical factors. The prudent clinical oncologist should use MBED
as a guide during clinical decisions rather than as an absolute indicator. The advice of
acknowledged experts in radiobiological modelling should be sought in more compli-
cated clinical situations.
Despite these limitations, the MBED model provides a valid means of accounting for
modulated intrinsic radiosensitivity effects, which is preferable to neglecting them by
using a biologically uncorrected physical dose.
Furthermore, the method is not intrinsically associated with the disease, and can be
applied to any case by integrating traditional treatment plans and improving the overall
radiotherapy performances in combined treatments comprising radiosensitizing drugs.
Conclusion
During this computational study, the MBED method was introduced. The MBED pro-
vides a new tool to estimate the effects of heterogeneity on tumour radiosensitivity and
to assess the dose per fraction required for increased tumour radiosensitivity due to
EGFr over-expression. Where radiotherapy treatment is combined with radiosensitizing
drugs, MBED suggests that the fraction sizes modulated according to drug pharmaco-
kinetics will allow new schedules of dose fractionation to be more effective.
In conclusion, the MBED method could improve overall radiotherapy performances
and be utilised to perform more appropriate radiobiological analysis, particularly when
combined treatment comprising radiation and biological drugs is employed.
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